Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
29
WST Quote, Financials, Valuation and Earnings
Last price:
$243.75
Seasonality move
:
7.94%
Day range:
$241.91 - $247.18
52-week range:
$187.43 - $322.34
Dividend yield:
0.35%
P/E ratio:
35.89x
P/S ratio:
5.77x
P/B ratio:
5.53x
Volume:
760.8K
Avg. volume:
1.1M
1-year change:
20.42%
Market cap:
$17.6B
Revenue:
$3.1B
EPS (TTM):
$6.79
Analysts' Opinion
-
Consensus RatingWest Pharmaceutical Services, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $318.36, West Pharmaceutical Services, Inc. has an estimated upside of 30.57% from its current price of $243.83.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $265.00 representing -8.68% downside risk from its current price of $243.83.
Fair Value
-
According to the consensus of 14 analysts, West Pharmaceutical Services, Inc. has 30.57% upside to fair value with a price target of $318.36 per share.
WST vs. S&P 500
-
Over the past 5 trading days, West Pharmaceutical Services, Inc. has underperformed the S&P 500 by -1.32% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
West Pharmaceutical Services, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
West Pharmaceutical Services, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter West Pharmaceutical Services, Inc. reported revenues of $806M.
Earnings Growth
-
West Pharmaceutical Services, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter West Pharmaceutical Services, Inc. reported earnings per share of $1.82.
Enterprise value:
17.1B
EV / Invested capital:
4.88x
Price / LTM sales:
5.77x
EV / EBIT:
26.86x
EV / Revenue:
5.56x
PEG ratio (5yr expected):
23.15x
EV / Free cash flow:
36.47x
Price / Operating cash flow:
37.80x
Enterprise value / EBITDA:
21.16x
Gross Profit (TTM):
$1.1B
Return On Assets:
12.6%
Net Income Margin (TTM):
16.06%
Return On Equity:
17%
Return On Invested Capital:
15.36%
Operating Margin:
21.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $2.9B | $2.9B | $3.1B | $748.5M | $806M | |
| Gross Profit | $1.1B | $1B | $1.1B | $274.4M | $305.1M | |
| Operating Income | $716.5M | $596.2M | $636.6M | $170.6M | $176.3M | |
| EBITDA | $853.8M | $751.6M | $808M | $211.3M | $223.3M | |
| Diluted EPS | $7.88 | $6.69 | $6.79 | $1.77 | $1.82 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.7B | $1.9B | $1.9B | $1.5B | $2B | |
| Total Assets | $3.3B | $3.6B | $3.8B | $3.6B | $4.3B | |
| Current Liabilities | $594.1M | $519M | $671.8M | $550.4M | $654.9M | |
| Total Liabilities | $978.4M | $931.9M | $948.5M | $961.1M | $1.1B | |
| Total Equity | $2.3B | $2.7B | $2.9B | $2.7B | $3.2B | |
| Total Debt | $316M | $301.9M | $291.3M | $287.4M | $303.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $776.5M | $653.4M | $754.8M | $190.1M | $251.1M | |
| Cash From Investing | -$368.7M | -$378.7M | -$285.9M | -$104.8M | -$76.1M | |
| Cash From Financing | -$459.6M | -$622.6M | -$185.1M | -$68.9M | -$11.7M | |
| Free Cash Flow | $414.5M | $276.4M | $468.9M | $85.2M | $175M | |
WST
Sector
Market Cap
$17.6B
$25.2M
Price % of 52-Week High
75.64%
49.83%
Dividend Yield
0.35%
0%
Shareholder Yield
0.88%
-1.77%
1-Year Price Total Return
20.42%
-21.9%
Beta (5-Year)
1.181
0.499
Dividend yield:
0.35%
Annualized payout:
$0.85
Payout ratio:
12.11%
Growth streak:
33 years
Technicals
8-day SMA
Sell
Level
$246.00
200-day SMA
Sell
Level
$249.14
Bollinger Bands (100)
Sell
Level
251.06 - 281.76
Chaikin Money Flow
Buy
Level
536.1K
20-day SMA
Buy
Level
$241.01
Relative Strength Index (RSI14)
Sell
Level
46.26
ADX Line
Sell
Level
7.14
Williams %R
Neutral
Level
-44.5523
50-day SMA
Sell
Level
$259.44
MACD (12, 26)
Buy
Level
34.74
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
53K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.8896)
Buy
CA Score
(Annual)
Level (1.6685)
Buy
Beneish M-Score
(Annual)
Level (-2.8056)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-3.4145)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
West Pharmaceutical Services, Inc. engages in the manufacture and marketing of pharmaceuticals, biologics, vaccines, and consumer healthcare products. It operates through the Proprietary Products and Contract-Manufactured Products segments. The Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
Stock Forecast FAQ
In the current month, WST has received 11 Buy ratings 3 Hold ratings, and 0 Sell ratings. The WST average analyst price target in the past 3 months is $318.36.
-
Where Will West Pharmaceutical Services, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that West Pharmaceutical Services, Inc. share price will rise to $318.36 per share over the next 12 months.
-
What Do Analysts Say About West Pharmaceutical Services, Inc.?
Analysts are divided on their view about West Pharmaceutical Services, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that West Pharmaceutical Services, Inc. is a Sell and believe this share price will drop from its current level to $265.00.
-
What Is West Pharmaceutical Services, Inc.'s Price Target?
The price target for West Pharmaceutical Services, Inc. over the next 1-year time period is forecast to be $318.36 according to 14 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is WST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for West Pharmaceutical Services, Inc. is a Buy. 11 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of WST?
You can purchase shares of West Pharmaceutical Services, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase West Pharmaceutical Services, Inc. shares.
-
What Is The West Pharmaceutical Services, Inc. Share Price Today?
West Pharmaceutical Services, Inc. was last trading at $243.75 per share. This represents the most recent stock quote for West Pharmaceutical Services, Inc.. Yesterday, West Pharmaceutical Services, Inc. closed at $243.83 per share.
-
How To Buy West Pharmaceutical Services, Inc. Stock Online?
In order to purchase West Pharmaceutical Services, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get WST Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
WST
Sector
P/E ratio
35.89x
23.30x
PEG ratio
23.15x
-0.01x
P/B ratio
5.53x
1.78x
Price / LTM sales
5.77x
1.55x
Growth Metrics
WST
Sector
Revenue growth
7.68%
3.69%
Earnings growth
2.38%
9.95%
Revenue (5-year growth)
7.45%
6.38%
Earnings forecast
$1.83
-$0.19
Profitability
WST
Sector
Profitability FY 2025
$1.1B
$2.6M
Return on invested capital
15.36%
-33.25%
Return on assets
12.6%
-29.67%
Return on equity
17%
-38.66%
Earnings Date
Last Earnings Date
Feb
12
Next Earnings Date
Apr
23
Estimated Next Earnings Date
May
14
Balance Sheet
WST
Sector
Total cash
$791.3M
$25.1M
Short term investments
--
$24M
Total assets
$4.3B
$72.5M
Long term debt
$303.5M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 2.23% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 0.38% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is up 0.8% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
